Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $14.01 and traded as high as $16.93. Benitec Biopharma shares last traded at $15.92, with a volume of 63,956 shares.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on BNTC. JMP Securities reissued a "market outperform" rating and issued a $20.00 target price on shares of Benitec Biopharma in a report on Thursday, May 15th. HC Wainwright reissued a "buy" rating and issued a $28.00 price objective on shares of Benitec Biopharma in a research note on Monday, May 19th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $23.83.
Get Our Latest Stock Report on Benitec Biopharma
Benitec Biopharma Stock Performance
The firm's 50-day moving average is $14.11 and its two-hundred day moving average is $12.66. The stock has a market cap of $432.60 million, a P/E ratio of -10.91 and a beta of 0.44.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.12. As a group, research analysts forecast that Benitec Biopharma Inc. will post -1.48 EPS for the current year.
Insiders Place Their Bets
In other Benitec Biopharma news, Director Suvretta Capital Management, L bought 900,000 shares of the stock in a transaction on Wednesday, March 26th. The stock was purchased at an average price of $13.00 per share, with a total value of $11,700,000.00. Following the acquisition, the director now owns 8,793,245 shares of the company's stock, valued at approximately $114,312,185. The trade was a 11.40% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.30% of the company's stock.
Hedge Funds Weigh In On Benitec Biopharma
Several institutional investors and hedge funds have recently made changes to their positions in the company. Suvretta Capital Management LLC lifted its holdings in shares of Benitec Biopharma by 1.5% during the 4th quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company's stock valued at $113,165,000 after purchasing an additional 130,956 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Benitec Biopharma by 269.0% during the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock worth $37,123,000 after acquiring an additional 2,142,643 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Benitec Biopharma by 198.5% during the fourth quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock worth $33,268,000 after acquiring an additional 1,739,904 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in Benitec Biopharma by 134.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after acquiring an additional 1,131,129 shares in the last quarter. Finally, Infinitum Asset Management LLC lifted its position in Benitec Biopharma by 435.7% in the 1st quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock valued at $14,636,000 after acquiring an additional 915,000 shares in the last quarter. Institutional investors and hedge funds own 52.19% of the company's stock.
About Benitec Biopharma
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Recommended Stories
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
